Lowest Price Guaranteed From USD 4,799
Published
October 2022
Slides
196
View Count
7802
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
The rare kidney diseases market is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period.. It is worth highlighting that the prevalence rate of rare kidney disorders (RKD) is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe. Despite their relatively low prevalence, these set of indications are believed to be one of the leading causes of renal diseases, along with diabetes and other rare genetic kidney disorders. The low disease incidence rate of such disorders, coupled to the lack of awareness among the general population, often leads to late or erroneous diagnosis. This, in turn, enables suboptimal therapeutic management, as well as compromised long-term outcomes. The aforementioned factors are some of the key reasons that are believed to be responsible for high mortality rates and severe compromise on chance of survival of a patient suffering with rare kidney disorders. It is worth mentioning that, post the onset of the COVID-19 pandemic, the treatment of patients affected with rare kidney disorders became even more challenging. This can be primarily attributed to the fact that the current treatment options for such indications are heavily reliant on regular patient visits to the hospitals or medical centers. Consequently, during the pandemic, a 30% increase in mortality rate was observed in affected patients. This increase in mortality has compelled players engaged in the pharmaceutical domain to undertake necessary research initiatives in order to identify novel drugs that can efficiently treat rare kidney disorders.
Given the complexity associated with conventional treatment options, such as dialysis, kidney transplant and biopsy, drug developers engaged in this domain have shifted their focus towards the development of drugs that can target a myriad of rare kidney disorders. It is worth highlighting that, since 2020, over seven drugs have received marketing approval for the treatment of rare kidney disorders; these are (in reverse chronological order of approval) Galafold® (Fabry disease, European Medicines Agency (EMA), 2021), Lupkynis™ (Lupus Nephritis (LN), United States Food and Drug Administration (USFDA), 2021), Sibnayal™ (distal Renal Tubular Acidosis (dRTA), EMA, 2021), Tarpeyo® (Immunoglobulin A Nephropathy (IgAN), USFDA, 2021), Benlysta® (LN, USFDA, 2020), Cystadrops® (Cystinosis, USFDA, 2020), and Ultomiris® (Atypical Hemolytic Uremic Syndrome (aHUS), Japan, 2020). Further, more than 90 candidates targeting rare kidney disorders are currently under clinical investigation, while several novel leads are being evaluated in early stages of development. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. In fact, over USD 4.5 billion has been invested in this domain since 2020. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.
Examples of key drugs developed by companies engaged in rare kidney diseases market (which have also been profiled in this market report; the complete list of drugs is available in the full report) include Atrasentan, Bardoxolone Methyl, Benlysta, Cosentyx®, Cozaar®, Crovalimab, Cystadrops®, Empaveli®, Galafold®, Ianalumab, Iptacopan, Lupkynis™, Narsoplimab, Pegunigalsidase Alfa, Rituxan®, Saphnelo™, Sibnayal™, Sparsentan, Tarpeyo®, Thiola® and Ultomiris®. This market report includes an easily searchable excel database of all the companies and their drugs for treating rare kidney diseases worldwide.
Several recent developments have taken place in the field of rare kidney disease. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The Rare Kidney Disorders Market - Distribution by Target Indications (IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and Others), Type of Molecule (Small Molecules and Biologics (Monoclonal Antibody, Hormone, Recombinant Protein, and Others)), Route of Administration (Oral, Intravenous, Subcutaneous, and Others) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast, 2022-2035 report features an extensive study of the current market landscape and the likely future potential associated with the rare kidney disorders market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. The below table highlights various market segmentations done in the report.
Report Attribute | Details | |
Forecast Period |
2022 – 2035 |
|
Target Indications |
Oncological disorders, IgA nephropathy, Lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy, C3 glomerulopathy, other disorders | |
Type of Molecule |
Small molecules, biologics | |
Route of Administration |
Oral, intravenous, subcutaneous, others | |
Key Geographical Regions | North America, Europe, Asia-Pacific, MENA, Latin America and Rest of the World |
Amongst other elements, the report features:
One of the key objectives of this report was to evaluate the current market size and the future potential associated with rare kidney disorders market, over the coming years. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across relevant parameters, such as [A] target indications (complement 3 glomerulopathy (C3G), FSGS, IgAN, LN, membranous nephropathy (MN)), [B] type of molecule (small molecules and biologics (monoclonal antibody, hormone, recombinant protein, and others)),[C] route of administration (oral, intravenous, subcutaneous and others) [D] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World (RoW)). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Rare Kidney Disorders
3.2. Key Historical Events
3.3. Factors Contributing to Rare Kidney Disorders
3.4. Rare Kidney Disorders: Target Indications
3.5. Rare Kidney Disorders: Applications of Omics Technology
3.6. Rare Kidney Disorders: Future Outlook
4. MARKET LANDSCAPE
4.1. Rare Kidney Disorders: List of Drugs
4.1.1. Analysis by Stage of Development
4.1.2. Analysis by Target Molecule
4.1.3. Analysis by Target Molecule and Route of Administration
4.1.4. Analysis by Target Indication
4.1.5. Analysis by Stage of Development and Target Indication
4.1.6. Analysis by Type of Target Molecule
4.1.7. Analysis by Stage of Development and Type of Target Molecule
4.2. Rare Kidney Disorders: List of Drug Developers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region
4.2.4. Most Active Players: Analysis by Number of Drugs
5. DRUG PROFILES
5.1. Benlysta
5.1.1. Company Overview
5.1.2. Drug Overview
5.1.3. Clinical Trial Information
5.1.4. Clinical Trial Results
5.1.5. Estimated Sales
5.2. Cystadrops®
5.2.1. Company Overview
5.2.2. Drug Overview
5.2.3. Clinical Trial Information
5.2.4. Clinical Trial Results
5.2.5. Estimated Sales
5.3. Galafold®
5.3.1. Company Overview
5.3.2. Drug Overview
5.3.3. Clinical Trial Information
5.3.4. Clinical Trial Results
5.3.5. Estimated Sales
5.4. Tarpeyo®
5.4.1. Company Overview
5.4.2. Drug Overview
5.4.3. Clinical Trial Information
5.4.4. Clinical Trial Results
5.4.5. Estimated Sales
5.5. Ultomiris®
5.5.1. Company Overview
5.5.2. Drug Overview
5.5.3. Clinical Trial Information
5.5.4. Clinical Trial Results
5.5.5. Estimated Sales
5.6. Thiola®
5.6.1. Company Overview
5.6.2. Drug Overview
5.6.3. Clinical Trial Information
5.6.4. Clinical Trial Results
5.6.5. Estimated Sales
5.7. Lupkynis™
5.7.1. Company Overview
5.7.2. Drug Overview
5.7.3. Clinical Trial Information
5.7.4. Clinical Trial Results
5.7.5. Estimated Sales
5.8. Sibnayal™
5.8.1. Company Overview
5.8.2. Drug Overview
5.8.3. Clinical Trial Information
5.8.4. Clinical Trial Results
5.8.5. Estimated Sales
5.9. Pegunigalsidase Alfa
5.9.1. Company Overview
5.9.2. Drug Overview
5.9.3. Clinical Trial Information
5.9.4. Clinical Trial Results
5.9.5. Estimated Sales
5.10. Saphnelo™
5.10.1. Company Overview
5.10.2. Drug Overview
5.10.3. Clinical Trial Information
5.10.4. Clinical Trial Results
5.10.5. Estimated Sales
5.11. Atrasentan
5.11.1. Company Overview
5.11.2. Drug Overview
5.11.3. Clinical Trial Information
5.11.4. Clinical Trial Results
5.11.5. Estimated Sales
5.12. Bardoxolone Methyl
5.12.1. Company Overview
5.12.2. Drug Overview
5.12.3. Clinical Trial Information
5.12.4. Clinical Trial Results
5.12.5. Estimated Sales
5.13. Crovalimab
5.13.1. Company Overview
5.13.2. Drug Overview
5.13.3. Clinical Trial Information
5.13.4. Clinical Trial Results
5.13.5. Estimated Sales
5.14. Ianalumab
5.14.1. Company Overview
5.14.2. Drug Overview
5.14.3. Clinical Trial Information
5.14.4. Estimated Sales
5.15. Cozaar®
5.15.1. Company Overview
5.15.2. Drug Overview
5.15.3. Clinical Trial Information
5.15.4. Clinical Trial Results
5.15.5. Estimated Sales
5.16. Cosentyx®
5.16.1. Company Overview
5.16.2. Drug Overview
5.16.3. Clinical Trial Information
5.16.4. Estimated Sales
5.17. Empaveli®
5.17.1. Company Overview
5.17.2. Drug Overview
5.17.3. Clinical Trial Information
5.17.4. Clinical Trial Results
5.17.5. Estimated Sales
5.18. Rituxan®
5.18.1. Company Overview
5.18.2. Drug Overview
5.18.3. Clinical Trial Information
5.18.4. Clinical Trial Results
5.18.5. Estimated Sales
5.19. Sparsentan
5.19.1. Company Overview
5.19.2. Drug Overview
5.19.3. Clinical Trial Information
5.19.4. Clinical Trial Results
5.19.5. Estimated Sales
5.20. Iptacopan
5.20.1. Company Overview
5.20.2. Drug Overview
5.20.3. Clinical Trial Information
5.20.4. Clinical Trial Results
5.20.5. Estimated Sales
5.21. Narsoplimab
5.21.1. Company Overview
5.21.2. Drug Overview
5.21.3. Clinical Trial Information
5.21.4. Clinical Trial Results
5.21.5. Estimated Sales
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Key Methodology and Parameters
6.2. Company Competitiveness Analysis: Biologic Developers (Peer Group 1)
6.3. Company Competitiveness Analysis: Small Molecule Developers (Peer Group 2)
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Rare Kidney Disorders: List of Partnerships
7.2. Analysis by Year of Partnership
7.3. Analysis by Type of Partnership
7.4. Analysis by Year and Type of Partnership
7.5. Analysis by Type of Partnership and Company Size
7.6. Analysis by Target Indication
7.7. Most Active Players: Analysis by Number of Partnerships
7.8. Analysis by Region
7.9. Analysis by Country
7.10. Intercontinental and Intracontinental Agreements
8. FUNDING AND INVESTMENTS
8.1. Rare Kidney Disorders: List of Funding and Investments
8.2. Cumulative Year-wise Trend of Funding, 2016 - 2022
8.3. Analysis of Instances by Type of Funding
8.4. Analysis of Instances by Type of Venture Funding
8.5. Analysis of Instances by Year of Funding and Type of Funding
8.6. Analysis by Type of Funding and Amount Invested
8.7. Analysis of Instances by Type of Investor
8.8. Analysis by Focus Area
8.9. Analysis by Region
8.11. Most Active Investors: Analysis by Number of Instances
8.12. Most Active Players: Analysis by Number of Instances
8.13. Most Active Players: Analysis by Amount Raised (USD Million)
9. CLINICAL TRIAL ANALYSIS
9.1. Methodology and Parameters
9.2. Cumulative Trend by Trial Registration Year, 2016 - 2022
9.3. Analysis by Target Indication
9.4. Analysis by Study Design
9.5. Analysis by Region
9.6. Analysis by Number of Trials, Phase of Development and Region
9.7. Analysis by Patient Age
9.8. Analysis by Trial Registration Year, Number of Trials and Region
9.9. Analysis by Trial Status and Phase of Development
9.10. Analysis of Patients Enrolled by Trial Registration Year
9.11. Analysis of Patients Enrolled by Phase of Development
9.12. Analysis by Number of Trials, Trial Status and Region
9.13. Analysis of Patients Enrolled by Region
9.14. Analysis of Patients Enrolled by Trial Status and Region
10. CLINICAL COMMERCIAL ATTRACTIVENESS
10.1. Scope and Limitations
10.2. Key Assumptions and Methodology
10.3.1. Clinical and Commercial Attractiveness Analysis: Atypical Hemolytic Uremic Syndrome
10.3.2. Clinical and Commercial Attractiveness Analysis: C3 Glomerulopathy
10.3.3. Clinical and Commercial Attractiveness Analysis: Cystinuria
10.3.4. Clinical and Commercial Attractiveness Analysis: Dense Deposit Disease
10.3.5. Clinical and Commercial Attractiveness Analysis: Fabry Disease
10.3.6. Clinical and Commercial Attractiveness Analysis: IgA Nephropathy
10.3.7. Clinical and Commercial Attractiveness Analysis: Lupus Nephritis
10.3.8. Clinical and Commercial Attractiveness Analysis: Refractory Gout
10.3.9. Clinical and Commercial Attractiveness Analysis: Other Target Indications
11. CASE STUDY
11.1. Scope and Key Parameters
11.2. Rare Kidney Disorders: List of Kidney Care Providers
11.3. Rare Kidney Disorders: Advantages of Kidney Care
11.4. Rare Kidney Disorders: Future Perspectives
11.5. Rare Kidney Disorders: Approach for Recent Initiatives
12. MARKET FORECAST
12.1. Scope and Limitations
12.2. Key Assumptions and Forecast Methodology
12.3. Global Rare Kidney Disorders Market, 2022-2035
12.4. Rare Kidney Disorders Market: Analysis by Type of Molecule, 2022-2035
12.4.1. Rare Kidney Disorders Market for Biologics, 2022-2035
12.4.2. Rare Kidney Disorders Market for Small Molecules, 2022-2035
12.5. Rare Kidney Disorders Market: Analysis by Route of Administration, 2022-2035
12.5.1. Rare Kidney Disorders Market for Oral Delivery, 2022-2035
12.5.2. Rare Kidney Disorders Market for Intravenous Delivery, 2022-2035
12.5.3. Rare Kidney Disorders Market for Subcutaneous Delivery, 2022-2035
12.5.4. Rare Kidney Disorders Market for Other Delivery Routes, 2022-2035
12.6. Rare Kidney Disorders Market: Analysis by Target Indication, 2022-2035
12.6.1. Rare Kidney Disorders Market for Alport Syndrome, 2022-2035
12.6.2. Rare Kidney Disorders Market for Atypical Hemolytic Uremic Syndrome, 2022-2035
12.6.3. Rare Kidney Disorders Market for C3 Glomerulopathy, 2022-2035
12.6.4. Rare Kidney Disorders Market for Cystinosis, 2022-2035
12.6.5. Rare Kidney Disorders Market for Cystinuria, 2022-2035
12.6.6. Rare Kidney Disorders Market for Dense Deposit Disease, 2022-2035
12.6.7. Rare Kidney Disorders Market for Distal Renal Tubular Acidosis, 2022-2035
12.6.8. Rare Kidney Disorders Market for Fabry Disease, 2022-2035
12.6.9. Rare Kidney Disorders Market for IgA Nephropathy, 2022-2035
12.6.12. Rare Kidney Disorders Market for Lupus Nephritis, 2022-2035
12.6.11. Rare Kidney Disorders Market for Refractory Gout, 2022-2035
12.7. Rare Kidney Disorders Market, 2022-2035: Analysis by Geography
12.7.1. Rare Kidney Disorders Market in North America, 2022-2035
12.7.2. Rare Kidney Disorders Market in Europe, 2022-2035
12.7.3. Rare Kidney Disorders Market in Asia-Pacific, 2022-2035
12.7.4. Rare Kidney Disorders Market in Rest of the World, 2022-2035
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Rare Kidney Disorders: Executive Summary
Figure 3.1 Key Historical Events
Figure 3.2 Factors Contributing to Rare Kidney Disorders
Figure 3.3 Rare Kidney Disorders: Target Indications
Figure 3.4 Rare Kidney Disorders: Applications of Omics Technology
Figure 3.5 Rare Kidney Disorders: Future Outlook
Figure 4.1 Rare Kidney Disorders: Distribution by Stage of Development
Figure 4.2 Rare Kidney Disorders: Distribution by Target Molecule
Figure 4.3 Rare Kidney Disorders: Distribution by Type of Target Molecule and Route of Administration
Figure 4.4 Rare Kidney Disorders: Distribution by Target Indication
Figure 4.5 Rare Kidney Disorders: Distribution by Stage of Development and Target Indication
Figure 4.6 Rare Kidney Disorders: Distribution by Type of Target Molecule
Figure 4.7 Rare Kidney Disorders: Distribution by Stage of Development and Type of Target Molecule
Figure 4.8 Rare Kidney Disorders: Distribution by Year of Establishment
Figure 4.9 Rare Kidney Disorders: Distribution by Company Size
Figure 4.10 Rare Kidney Disorders: Distribution by Region
Figure 4.11 Most Active Players: Analysis by Number of Drugs
Figure 5.1 Benlysta: Estimated Sales
Figure 5.2 Cystadrops®: Estimated Sales
Figure 5.3 Galafold®: Estimated Sales
Figure 5.4 Tarpeyo®: Estimated Sales
Figure 5.5 Ultomiris®: Estimated Sales
Figure 5.6 Thiola®: Estimated Sales
Figure 5.7 Lupkynis™: Estimated Sales
Figure 5.8 Sibnayal™: Estimated Sales
Figure 5.9 Pegunigalsidase Alfa: Estimated Sales
Figure 5.10 Saphnelo™: Estimated Sales
Figure 5.11 Atrasentan: Estimated Sales
Figure 5.12 Bardoxolone Methyl: Estimated Sales
Figure 5.13 Crovalimab: Estimated Sales
Figure 5.14 Ianalumab: Estimated Sales
Figure 5.15 Cozaar®: Estimated Sales
Figure 5.16 Cosentyx®: Estimated Sales
Figure 5.17 Empaveli®: Estimated Sales
Figure 5.18 Rituxan®: Estimated Sales
Figure 5.19 Sparsentan: Estimated Sales
Figure 5.20 Iptacopan: Estimated Sales
Figure 5.21 Narsoplimab: Estimated Sales
Figure 6.1 Company Competitiveness Analysis (Peer Group I): Biologic Developers
Figure 6.2 Company Competitiveness Analysis (Peer Group II): Small Molecules Developers
Figure 7.1 Partnership Analysis: Distribution by Year of Partnership
Figure 7.2 Partnership Analysis: Distribution by Type of Partnership
Figure 7.3 Partnership Analysis: Distribution by Year and Type of Partnership
Figure 7.4 Partnership Analysis: Distribution by Type of Partnership and Company Size
Figure 7.5 Partnership Analysis: Distribution by Target Indication
Figure 7.6 Most Active Players: Distribution by Number of Partnerships
Figure 7.7 Partnership Analysis: Regional Distribution
Figure 7.8 Partnership Analysis: Country-Wise Distribution
Figure 7.9 Partnership Analysis: Intercontinental and Intracontinental Agreements
Figure 8.1 Funding and Investments: Cumulative Distribution of Amount Invested by Year
Figure 8.2 Funding and Investments: Distribution of Instances by Type of Funding
Figure 8.3 Funding and Investments: Distribution of Instances by Type of Venture Funding
Figure 8.4 Funding and Investments: Distribution by Year and Type of Funding
Figure 8.5 Funding and Investments: Distribution of Instances by Type of Funding
Figure 8.6 Funding and Investments: Distribution of Instances by Type of Investor
Figure 8.7 Funding and Investments: Distribution by Amount Invested and Type of Molecule (USD Million)
Figure 8.8 Funding and Investments: Distribution by Focus Area
Figure 8.9 Funding and Investments: Distribution by Geography
Figure 8.10 Funding and Investments: Distribution by Amount Invested (USD Million) and Region (USD Million)
Figure 8.11 Most Active Investors: Analysis by Number of Instances
Figure 8.12 Most Active Players: Analysis by Number of Instances
Figure 8.13 Most Active Players: Analysis by Amount Raised (USD Million)
Figure 9.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 9.2 Clinical Trial Analysis: Distribution by Target Indication
Figure 9.3 Clinical Trial Analysis: Distribution by Study Design
Figure 9.4 Clinical Trial Analysis: Distribution by Region
Figure 9.5 Clinical Trial Analysis: Distribution by Number of Trials, Phase of Development and Region
Figure 9.6 Clinical Trial Analysis: Distribution by Patient Age
Figure 9.7 Clinical Trial Analysis: Distribution by Trial Registration Year, Number of Trials and Region
Figure 9.8 Clinical Trial Analysis: Distribution by Trial Status and Phase of Development
Figure 9.9 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year
Figure 9.10 Clinical Trial Analysis: Distribution of Patients Enrolled by Phase of Development
Figure 9.11 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
Figure 9.12 Clinical Trial Analysis: Patients Enrolled by Region
Figure 9.13 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Region
Figure 10.1 Clinical and Commercial Attractiveness Analysis
Figure 12.1 Global Rare Kidney Disorders Market, 2022-2035 (USD Million)
Figure 12.2 Rare Kidney Disorders Market: Distribution by Type of Molecule, 2022 and 2035
Figure 12.3 Rare Kidney Disorders Market for Biologics, 2022-2035 (USD Million)
Figure 12.4 Rare Kidney Disorders Market for Small Molecules, 2022-2035 (USD Million)
Figure 12.5 Rare Kidney Disorders Market: Distribution by Route of Administration, 2022 and 2035
Figure 12.6 Rare Kidney Disorders Market for Oral Delivery, 2022-2035 (USD Million)
Figure 12.7 Rare Kidney Disorders Market for Intravenous Delivery, 2022-2035 (USD Million)
Figure 12.8 Rare Kidney Disorders Market for Subcutaneous Delivery, 2022-2035 (USD Million)
Figure 12.9 Rare Kidney Disorders Market for Other Delivery Routes, 2022-2035 (USD Million)
Figure 12.10 Rare Kidney Disorders Market: Distribution by Target Indications, 2022 and 2035
Figure 12.11 Rare Kidney Disorders Market for Alport Syndrome, 2022-2035 (USD Million)
Figure 12.12 Rare Kidney Disorders Market for Atypical Hemolytic Uremic Syndrome, 2022-2035 (USD Million)
Figure 12.13 Rare Kidney Disorders Market for C3 Glomerulopathy, 2022-2035 (USD Million)
Figure 12.14 Rare Kidney Disorders Market for Cystinosis, 2022-2035 (USD Million)
Figure 12.15 Rare Kidney Disorders Market for Cystinuria, 2022-2035 (USD Million)
Figure 12.16 Rare Kidney Disorders Market for Dense Deposit Disease, 2022-2035 (USD Million)
Figure 12.17 Rare Kidney Disorders Market for distal Renal Tubular Acidosis, 2022-2035 (USD Million)
Figure 12.18 Rare Kidney Disorders Market for Fabry Disease, 2022-2035 (USD Million)
Figure 12.19 Rare Kidney Disorders Market for IgA Nephropathy, 2022-2035 (USD Million)
Figure 12.20 Rare Kidney Disorders Market for Lupus Nephritis, 2022-2035 (USD Million)
Figure 12.21 Rare Kidney Disorders Market for Refractory Gout, 2022-2035 (USD Million)
Figure 12.22 Rare Kidney Disorders Market: Distribution by Geography, 2022 and 2035
Figure 12.23 Rare Kidney Disorders Market in North America, 2022-2035 (USD Million)
Figure 12.24 Rare Kidney Disorders Market in Europe, 2022-2035 (USD Million)
Figure 12.25 Rare Kidney Disorders Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 12.26 Rare Kidney Disorders Market in Rest of the World, 2022-2035 (USD Million)
Table 3.1 Rare Kidney Disorders: List of Drugs
Table 4.1 Rare Kidney Disorders: List of Drugs
Table 4.2 Rare Kidney Disorders: List of Drug Developers
Table 5.1 Benlysta: Clinical Trial Information
Table 5.2 Cystadrops®: Clinical Trial Information
Table 5.3 Galafold®: Clinical Trial Information
Table 5.4 Tarpeyo®: Clinical Trial Information
Table 5.5 Ultomiris®: Clinical Trial Information
Table 5.6 Thiola®: Clinical Trial Information
Table 5.7 Lupkynis™: Clinical Trial Information
Table 5.8 Sibnayal™: Clinical Trial Information
Table 5.9 Pegunigalsidase Alfa: Clinical Trial Information
Table 5.10 Saphnelo™: Clinical Trial Information
Table 5.11 Atrasentan: Clinical Trial Information
Table 5.12 Bardoxolone Methyl: Clinical Trial Information
Table 5.13 Crovalimab: Clinical Trial Information
Table 5.14 Ianalumab: Clinical Trial Information
Table 5.15 Cozaar®: Clinical Trial Information
Table 5.16 Cosentyx®: Clinical Trial Information
Table 5.17 Empaveli®: Clinical Trial Information
Table 5.18 Rituxan®: Clinical Trial Information
Table 5.19 Sparsentan: Clinical Trial Information
Table 5.20 Iptacopan: Clinical Trial Information
Table 5.21 Narsoplimab: Clinical Trial Information
Table 7.1 Rare Kidney Disorders: List of Partnerships and Collaborations
Table 8.1 Rare Kidney Disorders: List of Funding and Investments
Table 11.1 Rare Kidney Disorders: List of Kidney Care Companies
The following companies / institutes / government bodies and organizations have been mentioned in this report: